Filing Flows › Celldex Therapeutics (CLDX) › Q1 2026 › vs Q4 2025
Celldex Therapeutics (CLDX) Q1 2026 vs Q4 2025 (quarter over quarter)
Celldex Therapeutics's revenue fell $106K (-88%) from $121K in Q4 2025 to $15K in Q1 2026.
Celldex Therapeutics, Q1 2026: revenue $15K (-98% year over year), net loss $78.7M, operating cash flow −$65.6M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $15K | $121K | −$106K | -88% |
| Other income, net | $5.8M | $5.8M | −$86K | -1% |
| Net loss | $78.7M | $81.3M | −$2.6M | -3% |
| Costs & expenses | $84.5M | $87.3M | −$2.8M | -3% |
| Operating costs | $84.5M | $87.3M | −$2.8M | -3% |
| Research & development | $73.0M | $75.3M | −$2.3M | -3% |
| General & admin | $11.4M | $11.9M | −$492K | -4% |
| Operating cash sources | $78.7M | $81.3M | −$2.6M | -3% |
| Depreciation & amortization | $854K | $816K | $38K | +5% |
| Share-based compensation | $8.5M | $8.9M | −$386K | -4% |
| Working capital & other | $3.7M | $7.7M | −$3.9M | -51% |
| Cash used in operations | $65.6M | $63.9M | $1.6M | +3% |
| Net loss absorbed | $78.7M | $81.3M | −$2.6M | -3% |
Questions
How much did Celldex Therapeutics's revenue grow quarter over quarter in Q1 2026?
Celldex Therapeutics's revenue fell $106K (-88%) from $121K in Q4 2025 to $15K in Q1 2026.